CL2023003603A1 - Terapia de combinación de un inhibidor de mat2a y uno de prmt tipo ii - Google Patents
Terapia de combinación de un inhibidor de mat2a y uno de prmt tipo iiInfo
- Publication number
- CL2023003603A1 CL2023003603A1 CL2023003603A CL2023003603A CL2023003603A1 CL 2023003603 A1 CL2023003603 A1 CL 2023003603A1 CL 2023003603 A CL2023003603 A CL 2023003603A CL 2023003603 A CL2023003603 A CL 2023003603A CL 2023003603 A1 CL2023003603 A1 CL 2023003603A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitor
- mat2a
- prmt
- combination therapy
- type
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- ZTNQNZDNHUAVEI-UHFFFAOYSA-N CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 Chemical compound CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 ZTNQNZDNHUAVEI-UHFFFAOYSA-N 0.000 title 1
- 229940125535 MAT2A inhibitor Drugs 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 abstract 3
- 239000013066 combination product Substances 0.000 abstract 3
- 229940127555 combination product Drugs 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000003708 Protein arginine N-methyltransferase Human genes 0.000 abstract 1
- 108020000912 Protein arginine N-methyltransferase Proteins 0.000 abstract 1
- 101710167557 S-adenosylmethionine synthase isoform type-2 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196008P | 2021-06-02 | 2021-06-02 | |
| US202263362438P | 2022-04-04 | 2022-04-04 | |
| US202263364360P | 2022-05-09 | 2022-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003603A1 true CL2023003603A1 (es) | 2024-07-12 |
Family
ID=84323602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003603A CL2023003603A1 (es) | 2021-06-02 | 2023-12-01 | Terapia de combinación de un inhibidor de mat2a y uno de prmt tipo ii |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240108626A1 (enExample) |
| EP (1) | EP4347569A4 (enExample) |
| JP (1) | JP2024521920A (enExample) |
| KR (1) | KR20240019172A (enExample) |
| AU (1) | AU2022287057A1 (enExample) |
| BR (1) | BR112023025360A2 (enExample) |
| CA (1) | CA3220160A1 (enExample) |
| CL (1) | CL2023003603A1 (enExample) |
| IL (1) | IL308853A (enExample) |
| MX (1) | MX2023014405A (enExample) |
| WO (1) | WO2022256806A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| EP4347569A4 (en) * | 2021-06-02 | 2025-03-26 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
| WO2023125540A1 (zh) * | 2021-12-27 | 2023-07-06 | 南京明德新药研发有限公司 | 吡唑-1(2h)-酞嗪酮类化合物及其应用 |
| EP4469447A1 (en) * | 2022-01-26 | 2024-12-04 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2023202626A1 (zh) * | 2022-04-22 | 2023-10-26 | 北京望实智慧科技有限公司 | 稠和哒嗪酮化合物作为prmt5抑制剂 |
| WO2023246873A1 (zh) * | 2022-06-23 | 2023-12-28 | 南京明德新药研发有限公司 | 氨基取代的杂芳基衍生物及其应用 |
| EP4549440A4 (en) * | 2022-07-01 | 2026-04-22 | Cytosinlab Therapeutics Co Ltd | CLASS OF PRMT5 INHIBITORS AND THEIR USES |
| WO2024027703A1 (zh) * | 2022-08-02 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | 一种prmt5抑制剂、其制备方法及应用 |
| AU2023366908A1 (en) * | 2022-10-25 | 2025-05-08 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| CN120265615A (zh) * | 2022-11-29 | 2025-07-04 | 正大天晴药业集团股份有限公司 | 含有二氢酞嗪的化合物 |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
| TW202440126A (zh) * | 2022-11-30 | 2024-10-16 | 美商安進公司 | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療 |
| CN120457124A (zh) * | 2022-12-30 | 2025-08-08 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| CN120476118A (zh) * | 2023-01-17 | 2025-08-12 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| MX2025012140A (es) * | 2023-04-13 | 2026-02-03 | Ideaya Biosciences Inc | Terapia combinada que comprende un inhibidor de mat2a y un inhibidor de la topoisomerasa, un inhibidor del empalme sulfonamida, o un inhibidor de kif18 |
| TW202442231A (zh) * | 2023-04-28 | 2024-11-01 | 智擎生技製藥股份有限公司 | Mta協同性prmt5抑制劑 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN116283800B (zh) * | 2023-05-16 | 2023-07-18 | 英矽智能科技(上海)有限公司 | 氧代喹唑啉类化合物及其应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN121646468A (zh) * | 2023-08-08 | 2026-03-10 | 米拉蒂治疗公司 | 用于治疗恶性周围神经鞘瘤的方法和组合物 |
| WO2025059579A1 (en) * | 2023-09-15 | 2025-03-20 | Ideaya Biosciences, Inc. | Methods of treating mat2a related diseases |
| WO2025061102A1 (zh) * | 2023-09-20 | 2025-03-27 | 西藏海思科制药有限公司 | 一种含氰基的杂环化合物及其用途 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025098450A1 (zh) * | 2023-11-08 | 2025-05-15 | 北京泰德制药股份有限公司 | Prmt5抑制剂及其制备方法 |
| WO2025113704A1 (zh) * | 2023-12-01 | 2025-06-05 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
| WO2025157286A1 (zh) * | 2024-01-26 | 2025-07-31 | 上海湃隆生物科技有限公司 | 包含prmt5抑制剂和mat2a抑制剂的药物组合物 |
| WO2025166308A1 (en) * | 2024-01-31 | 2025-08-07 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217297A1 (en) * | 2024-04-09 | 2025-10-16 | Tango Therapeutics, Inc. | Prmt5 inhibitors for use in methods of treating mta-accumulating cancer |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025250569A1 (en) * | 2024-05-29 | 2025-12-04 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096165A1 (en) * | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
| WO2020123395A1 (en) * | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| IL290341B2 (en) * | 2019-09-12 | 2024-11-01 | Mirati Therapeutics Inc | Mta-cooperative prmt5 inhibitors |
| KR20220086628A (ko) * | 2019-10-22 | 2022-06-23 | 루핀 리미티드 | Prmt5 저해제의 약학적 조합물 |
| US12403137B2 (en) * | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| EP4347569A4 (en) * | 2021-06-02 | 2025-03-26 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
-
2022
- 2022-06-01 EP EP22817027.0A patent/EP4347569A4/en active Pending
- 2022-06-01 AU AU2022287057A patent/AU2022287057A1/en active Pending
- 2022-06-01 JP JP2023574589A patent/JP2024521920A/ja active Pending
- 2022-06-01 CA CA3220160A patent/CA3220160A1/en active Pending
- 2022-06-01 BR BR112023025360A patent/BR112023025360A2/pt unknown
- 2022-06-01 KR KR1020237045309A patent/KR20240019172A/ko active Pending
- 2022-06-01 WO PCT/US2022/072693 patent/WO2022256806A1/en not_active Ceased
- 2022-06-01 IL IL308853A patent/IL308853A/en unknown
- 2022-06-01 MX MX2023014405A patent/MX2023014405A/es unknown
-
2023
- 2023-11-03 US US18/501,729 patent/US20240108626A1/en active Pending
- 2023-12-01 CL CL2023003603A patent/CL2023003603A1/es unknown
-
2024
- 2024-01-05 US US18/405,638 patent/US12115163B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12115163B2 (en) | 2024-10-15 |
| WO2022256806A1 (en) | 2022-12-08 |
| KR20240019172A (ko) | 2024-02-14 |
| US20240173326A1 (en) | 2024-05-30 |
| JP2024521920A (ja) | 2024-06-04 |
| US20240108626A1 (en) | 2024-04-04 |
| AU2022287057A1 (en) | 2023-12-14 |
| EP4347569A1 (en) | 2024-04-10 |
| BR112023025360A2 (pt) | 2024-02-20 |
| CA3220160A1 (en) | 2022-12-08 |
| MX2023014405A (es) | 2024-04-30 |
| IL308853A (en) | 2024-01-01 |
| EP4347569A4 (en) | 2025-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003603A1 (es) | Terapia de combinación de un inhibidor de mat2a y uno de prmt tipo ii | |
| CO2020009625A2 (es) | Inhibidor de fap | |
| CO2021009882A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
| MX2020009757A (es) | Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades. | |
| ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
| MX2019011061A (es) | Compuestos útiles en el tratamiento o prevención de un trastorno mediado por la proteína arginina metil-transferasa 5 (prmt5). | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112019000598A2 (pt) | rna para terapia de câncer | |
| MX2019011221A (es) | Terapia de combinacion para el tratamiento o prevencion de tumores. | |
| ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| PT4106757T (pt) | Métodos que envolvem o inibidor da elastase neutrofílica alvelestat para o tratamento de doenças respiratórias mediadas pela deficiência de alfa 1 antitripsina | |
| BR112018069927A2 (pt) | terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação | |
| BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| CL2021003474A1 (es) | Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria | |
| CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
| CO2022000426A2 (es) | Inhibidores de calicreína plasmática | |
| MX2019011982A (es) | Compuesto macrociclico y sus usos. | |
| CL2025001869A1 (es) | Uso de diferentes compuestos inhibidores de quinasas para tratar cáncer. | |
| BR112022023187A2 (pt) | Compostos para o tratamento da sars | |
| CL2025000366A1 (es) | Composiciones y metodos para el tratamiento de presicion del cancer | |
| CO2025009288A2 (es) | Productos terapéuticos dirigidos al receptor de somatostatina subtipo 2 (sst2r) y usos de la misma | |
| BR112019011350A2 (pt) | terapia de combinação | |
| ECSP23076552A (es) | Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos |